Effect of Depo-Provera or Microgynon on the painful crises of sickle cell anemia patients.
Forty-three homozygous (SS) female sickle cell anemic patients with a history of at least one painful crisis per month and desiring a reversible contraceptive were administered DMPA/3 months or Microgynon monthly. A third group of 16 surgically sterilized patients served as control. Patients were followed for 1 year to assess possible effects of the contraceptives on the patients' painful crises. No changes were observed in any of the groups in the hematological parameters. At the end of the study, 70% of the patients receiving DMPA were pain-free and only 16% of those still reporting painful crises rated them as intense. Patients receiving Microgynon also had an amelioration of the painful crises, although at a lower rate; after 12 months, 45.5% still experienced some crises. Although less marked than in the other groups, 50.5% of the control patients also reported an improvement of their painful crisis, which may be a result of closer medical care.
de Abood
M
M
Hematology Section, Social Security Hospital, Madrid.
de Castillo
Z
Z
Guerrero
F
F
Espino
M
M
Austin
K L
KL
D000293:Adolescent; D000328:Adult; D000698:Analgesia; D000755:Anemia, Sickle Cell / Q000188:drug therapy*; D003271:Contraceptive Agents, Female; D003277:Contraceptives, Oral, Combined; D019304:Ethinyl Estradiol-Norgestrel Combination / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D006720:Homozygote; D006801:Humans; D017258:Medroxyprogesterone Acetate / Q000008:administration & dosage / Q000627:therapeutic use*
D003271:Contraceptive Agents, Female; D003277:Contraceptives, Oral, Combined; D019304:Ethinyl Estradiol-Norgestrel Combination; D017258:Medroxyprogesterone Acetate